Sage Therapeutics, a prominent biotech company based in Cambridge, Massachusetts, has announced that it will lay off 338 employees – the vast majority of its workforce – as part of a transition leading up to its acquisition by Supernus Pharmaceuticals in a deal valued at up to $795 million. The reduction in staff, effective August 22, 2025, was formally reported to the state last week, coming shortly after the acquisition was publicly disclosed.

Sage reported a total full-time staff headcount of 353 as of February, widely recognized for its leading efforts in neuroscience and psychiatric drug discovery. The layoffs mark one of the largest in Boston’s life sciences sector in 2025, highlighting ongoing challenges in biotech following sharp funding contractions and R&D risks.

The Supernus Acquisition – Background and Details

Supernus Pharmaceuticals, a Maryland-based specialty pharma company with a three-decade track record in the central nervous system (CNS) drug market, announced the definitive agreement to acquire Sage Therapeutics on June 16. The deal promises to combine Supernus’s established CNS products – including marketed therapies for epilepsy, migraine, ADHD, and Parkinson’s disease – with Sage’s innovative pipeline.

The centerpiece of the acquisition is Sage’s FDA-approved drug Zurzuvae (zuranolone), which in 2023 became the first oral treatment specifically approved for postpartum depression (PPD). The drug, codeveloped with Biogen, represents a significant advance for mental health therapies and offers Supernus a unique market position.

“This acquisition represents a major step in bolstering our future growth,” Supernus CEO Jack Khattar said in a statement, citing Zurzuvae’s commercial potential and the complementary nature of Sage’s CNS pipeline with Supernus’s existing portfolio.

The deal, expected to close in the third quarter of 2025 pending regulatory approval and shareholder consent, follows an intense period of consolidation across the biotech industry. Recent months have seen several headline-making M&A transactions as mid-size and large pharmaceutical firms aim to expand their portfolios and offset risks associated with drug development failures.

Sage Therapeutics: A Tumultuous Road

Founded in 2010, Sage Therapeutics rapidly positioned itself as a leading innovator in brain health, going public in 2014. Its fortunes peaked on the promise of zuranolone for both postpartum depression and, more significantly, major depressive disorder (MDD), a far larger market. However, in August 2023, the U.S. Food and Drug Administration approved Zurzuvae exclusively for PPD, while denying its use for MDD. This regulatory setback had severe financial consequences for Sage, whose share price plummeted nearly 50% overnight. In response, the company announced a round of layoffs, reducing its workforce by nearly 40% just days later.

Compounding its challenges, Sage discontinued development of a Parkinson’s disease drug in April 2024 after failing a mid-stage clinical study. The company also reportedly rejected a $469 million acquisition offer from Biogen in January 2025, determined to hold out for improved terms or a more synergistic buyer.

These events epitomize the volatility of the drug development business, where even promising science and compelling clinical needs cannot guarantee success. Industry analysts note that biotech layoffs across Massachusetts have risen sharply since late 2023, as investors demand faster returns and regulatory hurdles persist.

Industry Context: Biotech M&A Surges Despite Sector Headwinds

The acquisition of Sage Therapeutics comes amid a broader acceleration of M&A activity in biotechnology. 2024 and 2025 have seen a series of blockbuster deals, including Eli Lilly’s $1.3 billion purchase of gene-editing startup Verve Therapeutics and Pfizer’s multibillion-dollar oncology acquisitions. According to Boston Consulting Group, biotech M&A deal volume was up 22% year-over-year as firms sought to replenish pipelines and capitalize on undervalued assets.

However, job cuts have followed these transactions, with many acquired companies shuttering duplicative operations or halting in-house R&D. Sage’s layoff announcement aligns with a trend that has seen thousands of Boston-area life science jobs eliminated since 2023, even as the region remains a global innovation hub.

Despite sector turbulence, investor interest in breakthrough central nervous system therapies remains high due to rising mental health awareness, unmet needs, and significant market opportunities. Postpartum depression, for example, affects roughly one in eight new mothers in the United States, with the American Psychological Association calling for improved treatment access. A successful oral therapy for PPD, such as Zurzuvae, could be a game-changer both clinically and commercially.

What’s Next for Sage Employees and Local Biotech?

Affected Sage workers have been notified under the federal Worker Adjustment and Retraining Notification (WARN) Act. While some may be integrated into Supernus or find new roles within the region’s robust biotech startup ecosystem, the layoffs serve as a stark reminder of the risks and volatility inherent in the sector.

Massachusetts authorities, along with the MassBio trade group, are focusing on retraining initiatives and networking programs to support displaced life sciences talent. Regional leaders stress that, even amid restructuring, Boston and Cambridge remain magnets for capital, talent, and new company formation, aided by world-class research centers such as MIT and Harvard.

Supernus, meanwhile, is expected to focus on maximizing sales of Zurzuvae and accelerating late-stage development of other CNS pipeline assets initially advanced by Sage. Industry observers will watch closely for additional consolidation, as both small and large companies seek to balance innovation with pragmatic commercial strategies.